Pharmacokinetic analyses of carboplatin in a patient with cancer of the fallopian tubes undergoing hemodialysis: A case report

Wada,Takuma; Fukuda,Takeshi; Kawanishi,Masaru; Tasaka,Reiko; Imai,Kenji; Yamauchi,Makoto; Kasai,Mari; Hashiguchi,Yasunori; Ichimura,Tomoyuki; Yasui,Tomoyo; Sumi,Toshiyuki

doi:10.3892/br.2016.714

August-2016 Volume 5 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

August-2016 Volume 5 Issue 2

Full Size Image

Case Report

Pharmacokinetic analyses of carboplatin in a patient with cancer of the fallopian tubes undergoing hemodialysis: A case report

Authors:
- Takuma Wada
- Takeshi Fukuda
- Masaru Kawanishi
- Reiko Tasaka
- Kenji Imai
- Makoto Yamauchi
- Mari Kasai
- Yasunori Hashiguchi
- Tomoyuki Ichimura
- Tomoyo Yasui
- Toshiyuki Sumi
View Affiliations / Copyright

Affiliations: Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine, Osaka 545‑8585, Japan
Pages: 199-202
|
Published online on: July 4, 2016

https://doi.org/10.3892/br.2016.714
Expand metrics +

Abstract

Opportunities for patients undergoing hemodialysis to receive chemotherapy are increasing. A combination of paclitaxel and carboplatin (TC) is first‑line chemotherapy in patients with Müllerian cancer. However, the optimal dose and time interval between the end of carboplatin administration and initiation of hemodialysis remains to be elucidated. TC was administered to a patient with fallopian tube cancer undergoing hemodialysis. The paclitaxel regimen was determined to be 135 mg/m2 (total of 210 mg) over 3 h. After paclitaxel administration, 125 mg of carboplatin was administered over 1 h to achieve a target area under the concentration‑time curve (AUC) of 5.0 mg•min/ml using the Calvert formula. The time interval between the end of carboplatin administration and hemodialysis initiation was 1 h at the first cycle, 16 h at the second cycle and 20 h at the third cycle, and the AUC obtained was 2.86, 4.16 and 6.0 mg•min/ml, respectively. The desired AUC of free platinum was demonstrated and only mild side effects were observed at the third cycle. Therefore, hemodialysis was initiated 20 h after completion of carboplatin infusion at cycles 4‑6. The total chemotherapy planned was completed without severe adverse events. Measurement of the concentration of free platinum subsequent to administration is useful for determination of the optimal dose of carboplatin and time interval following administration to obtain an adequate AUC. The present study suggests that carboplatin can be administered to a patient undergoing hemodialysis, and that an adequate interval between the end of carboplatin administration and hemodialysis initiation may be ~20 h.

View Figures

View References

1	Watanabe M, Aoki Y, Tomita M, Sato T, Takaki Y, Kato N, Kikuchi M, Kase H and Tanaka K: Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer. Gynecol Oncol. 84:335–338. 2002. View Article : Google Scholar : PubMed/NCBI
2	Tomita M, Kurata H, Aoki Y, Tanaka K and Kazama JJ: Pharmacokinetics of paclitaxel and cisplatin in a hemodialysis patient with recurrent ovarian cancer. Anticancer Drugs. 12:485–487. 2001. View Article : Google Scholar : PubMed/NCBI
3	Yoshida H, Sumi T, Abe K and Ishiko O: Pharmacokinetics of paclitaxel and carboplatin in a hemodialysis patient with advanced ovarian cancer. Eur J Gynaecol Oncol. 30:583–585. 2009.PubMed/NCBI
4	Kodama J, Sasaki A, Masahiro S, Seki N, Kusumoto T, Nakamura K, Hongo A and Hiramatsu Y: Pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in a patient with advanced epithelial ovarian cancer undergoing hemodialysis. Oncol Lett. 1:511–513. 2010. View Article : Google Scholar : PubMed/NCBI
5	Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME and Wiltshaw E: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol. 7:1748–1756. 1989.PubMed/NCBI
6	LeRoy AF, Wehling ML, Sponseller HL, Friauf WS, Solomon RE, Dedrick RL, Litterst CL, Gram TE, Guarino AM and Becker DA: Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med. 18:184–191. 1977. View Article : Google Scholar : PubMed/NCBI
7	National Cancer Institute. National Institutes of Health, US Department of Health and Human Services: Common terminology criteria for adverse events (CTCAE) version 4.0. NIH Publication no. 09–5410. Bethesda, MD: 2009.
8	Longnecker SM, Donehower RC, Cates AE, Chen TL, Brundrett RB, Grochow LB, Ettinger DS and Colvin M: High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep. 71:53–59. 1987.PubMed/NCBI
9	Woo MH, Gregornik D, Shearer PD, Meyer WH and Relling MV: Pharmacokinetics of paclitaxel in an anephric patient. Cancer Chemother Pharmacol. 43:92–96. 1999. View Article : Google Scholar : PubMed/NCBI
10	Hiraike M, Hiraki Y, Misumi N, Hanada K, Tsuji Y, Kamimura H, Karube Y and Kashiwabara K: Pharmacokinetics of carboplatin in a hemodialysis patient with small-cell lung cancer. Cancer Chemother Pharmacol. 69:845–848. 2012. View Article : Google Scholar : PubMed/NCBI
11	Koeller JM, Trump DL, Tutsch KD, Earhart RH, Davis TE and Tormey DC: Phase I clinical trial and pharmacokinetics of carboplatin (NSC 241240) by single monthly 30-minute infusion. Cancer. 57:222–225. 1986. View Article : Google Scholar : PubMed/NCBI
12	Suzuki S, Koide M, Sakamoto S and Matsuo T: Pharmacokinetics of carboplatin and etoposide in a haemodialysis patient with Merkel-cell carcinoma. Nephrol Dial Transplant. 12:137–140. 1997. View Article : Google Scholar : PubMed/NCBI
13	Chatelut E, Rostaing L, Gualano V, Vissac T, De Forni M, Ton-That H, Suc JM, Houin G and Canal P: Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency. Nephron. 66:157–161. 1994. View Article : Google Scholar : PubMed/NCBI
14	Yokoyama Y, Futagami M, Higuchi T and Mizunuma H: Pharmacokinetic analysis of paclitaxel and carboplatin in a patient with advanced ovarian cancer during hemodialysis - case report. Eur J Gynaecol Oncol. 27:437–439. 2006.PubMed/NCBI
15	Fong MK, Fetterly GJ Jr, McDougald LJ and Iyer RV: Carboplatin pharmacokinetics in a patient receiving hemodialysis. Pharmacotherapy. 34:e9–e13. 2014. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Pharmacokinetic analyses of carboplatin in a patient with cancer of the fallopian tubes undergoing hemodialysis: A case report

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles